Evidence map›Paper›PMID 33120981›Full record

ArticleViruses2020

High Rate of Circulating MERS-CoV in Dromedary Camels at Slaughterhouses in Riyadh, 2019.

Taibah A Aljasim, Abdulrahman Almasoud, Haya A Aljami, Mohamed W Alenazi, Suliman A Alsagaby, Asma N Alsaleh, Naif Khalaf Alharbi

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. MERS-COV in the Middle East, a one health concept approach.One health (Amsterdam, Netherlands) · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Taibah A AljasimVaccine Development Unit, Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh 11564, Saudi Arabia.
Abdulrahman AlmasoudVaccine Development Unit, Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh 11564, Saudi Arabia.
Haya A AljamiVaccine Development Unit, Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh 11564, Saudi Arabia.
Mohamed W AlenaziVaccine Development Unit, Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh 11564, Saudi Arabia.
Suliman A AlsagabyDepartment of Medical Laboratories Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11952, Saudi Arabia.ORCID 0000-0002-2242-5638
Asma N AlsalehCollege of Science, King Saud University, Riyadh 11564, Saudi Arabia.
Naif Khalaf AlharbiVaccine Development Unit, Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh 11564, Saudi Arabia.ORCID 0000-0002-6049-3383
King Saud bin Abdulaziz University for Health Sciences · SAKing Saud University · SAMajmaah University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MERS-CoV is a zoonotic virus that has emerged in humans in 2012 and caused severe respiratory illness with a mortality rate of 34.4%. Since its appearance, MERS-CoV has been reported in 27 countries and most of these cases were in Saudi Arabia. So far, dromedaries are considered to be the intermediate host and the only known source of human infection. This study was designed to determine the seroprevalence and the infection rate of MERS-CoV in slaughtered food-camels in Riyadh, Saudi Arabia. A total of 171 nasal swabs along with 161 serum samples were collected during the winter; from January to April 2019. Nasal swabs were examined by Rapid test and RT-PCR to detect MERS-CoV RNA, while serum samples were tested primarily using S1-based ELISA Kit to detect MERS-CoV (IgG) antibodies and subsequently by MERS pseudotyped viral particles (MERSpp) neutralization assay for confirmation. Genetic diversity of the positive isolates was determined based on the amplification and sequencing of the spike gene. Our results showed high prevalence (38.6%) of MERS-CoV infection in slaughtered camels and high seropositivity (70.8%) during the time of the study. These data indicate previous and ongoing MERS-CoV infection in camels. Phylogenic analysis revealed relatively low genetic variability among our isolated samples. When these isolates were aligned against published spike sequences of MERS-CoV, deposited in global databases, there was sequence similarity of 94%. High seroprevalence and high genetic stability of MERS-CoV in camels indicating that camels pose a public health threat. The widespread MERS-CoV infections in camels might lead to a risk of future zoonotic transmission into people with direct contact with these infected camels. This study confirms re-infections in camels, highlighting a challenge for vaccine development when it comes to protective immunity.

Indexed as

AbattoirsAnimalsAntibodies, ViralCamelusCoronavirus InfectionsDisease ReservoirsEnzyme-Linked Immunosorbent AssayGenetic VariationMiddle East Respiratory Syndrome CoronavirusPrevalenceRNA, ViralSaudi ArabiaSeroepidemiologic StudiesSpike Glycoprotein, CoronavirusAntibodies, ViralRNA, ViralSpike Glycoprotein, CoronaviruscamelELISAMERS-CoVRT-PCRseroprevalenceslaughterhousetransmission

Identifiers

PMID33120981
PMCPMC7692456
OpenAlexW3084562961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.